PMID- 36313782
OWN - NLM
STAT- MEDLINE
DCOM- 20221101
LR  - 20221102
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in 
      patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
PG  - 994944
LID - 10.3389/fendo.2022.994944 [doi]
LID - 994944
AB  - AIMS: Hyperglucagonemia occurs in the pathogenesis of type 2 diabetes mellitus 
      (T2DM). In this meta-analysis, we summarized the effects of DPP4 inhibitors on 
      glucagon levels in patients with T2DM. MATERIALS AND METHODS: Randomized 
      controlled trials (RCTs) comparing the influence of DPP4 inhibitors on 
      circulating glucagon levels with placebo or other oral antidiabetic drugs (OADs) 
      in patients with T2DM were identified by searches of Medline (PubMed), Embase 
      (Ovid), and CENTER (Cochrane Library). Only studies reporting changes in glucagon 
      level presented as total area under the curve (AUC(glucagon)) using a meal or 
      oral glucose tolerance test were included. Results were combined using a 
      random-effects model that incorporated potential heterogeneity among the included 
      studies. RESULTS: A total of 36 RCTs with moderate to high quality were included. 
      Overall, the numbers of T2DM patients included for the meta-analyses comparing 
      DPP4 inhibitors with placebo and other OADs were 4266 and 1652, respectively. 
      Compared to placebo, DPP4 inhibitors significantly reduced circulating glucagon 
      levels (standard mean difference [SMD]: -0.32, 95% CI: -0.40 to -0.24, P<0.001; 
      I(2 =) 28%). Analysis of subgroups revealed that study characteristics had no 
      significant effect on results, such as study design (parallel group or 
      crossover), number of patients, mean patient age, proportion of men, baseline 
      HbA1c, duration of diabetes, background therapy, treatment duration, or methods 
      for glucagon measurement (all P for subgroup differences >0.05). Moreover, DPP4 
      inhibitors significantly reduced glucagon levels compared to other OADs (SMD: 
      -0.35, 95% CI: -0.53 to -0.16, P<0.001; I(2) = 66%), and the reduction in 
      glucagon was greater in comparison with insulin secretagogues than in comparison 
      with non-insulin secretagogues (P for subgroup difference =0.03). SYSTEMATIC 
      REVIEW REGISTRATION: https://inplasy.com/, identifier INPLASY202280104. 
      CONCLUSIONS: DPP4 inhibitors are effective at reducing the circulating 
      postprandial glucagon level in T2DM patients.
CI  - Copyright (c) 2022 Chai, Zhang, Zhang, Carr, Zheng, Rajpathak and Ji.
FAU - Chai, Shangyu
AU  - Chai S
AD  - Merck Research Laboratories (MRL) Global Medical Affairs, Merck Sharp & Dohme 
      (MSD) China, Shanghai, China.
FAU - Zhang, Ruya
AU  - Zhang R
AD  - Merck Research Laboratories (MRL) Global Medical Affairs, Merck Sharp & Dohme 
      (MSD) China, Shanghai, China.
FAU - Zhang, Ye
AU  - Zhang Y
AD  - Merck Research Laboratories (MRL) Global Medical Affairs, Merck Sharp & Dohme 
      (MSD) China, Shanghai, China.
FAU - Carr, Richard David
AU  - Carr RD
AD  - Hatter Cardiovascular Institute, University College London, UK and Ulster 
      University, Coleraine, United Kingdom.
FAU - Zheng, Yiman
AU  - Zheng Y
AD  - Merck Research Laboratories (MRL) Global Medical Affairs, Merck Sharp & Dohme 
      (MSD) China, Shanghai, China.
FAU - Rajpathak, Swapnil
AU  - Rajpathak S
AD  - Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, United States.
FAU - Ji, Linong
AU  - Ji L
AD  - Department of Endocrinology, People's Hospital of Peking University, Beijing, 
      China.
LA  - eng
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20221012
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 9007-92-5 (Glucagon)
RN  - 0 (Secretagogues)
RN  - 0 (Hypoglycemic Agents)
RN  - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
SB  - IM
MH  - Male
MH  - Humans
MH  - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use/pharmacology
MH  - Glucagon
MH  - Secretagogues/therapeutic use
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Hypoglycemic Agents/pharmacology
MH  - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use
PMC - PMC9597445
OTO - NOTNLM
OT  - dipeptidyl peptidase-4 inhibitor
OT  - glucagon
OT  - hyperglucagonemia
OT  - meta-analysis
OT  - randomized controlled trials
COIS- SC, RZ, YZ and YMZ are employees of MSD China. SR is an employee of Merck Sharp & 
      Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, US. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2022/11/01 06:00
MHDA- 2022/11/02 06:00
PMCR- 2022/01/01
CRDT- 2022/10/31 05:05
PHST- 2022/07/15 00:00 [received]
PHST- 2022/09/21 00:00 [accepted]
PHST- 2022/10/31 05:05 [entrez]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/11/02 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.994944 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Oct 12;13:994944. doi: 
      10.3389/fendo.2022.994944. eCollection 2022.